Clinical trials: Primary Sjögren's Syndrome
Sjogren's Syndrome
Interstitial Lung Diseases in Primary Sjogren's Syndrome
Patients with pSS seen in the Division of Rheumatology, the second affiliated hospital of Zhejiang University, School of Medicine (SAHZU) during January 2016 to July 2018, were retrospectively reviewed.
- Trial name
- NCT04978883
- Testing
- No intervention
- Volunteers
- 170 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Primary Sjogrens Disease
A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome
The main purpose of the proposed study is to evaluate the efficacy of efgartigimod PH20 SC in patients with moderate-to-severe Primary Sjögren's Disease (pSjD).
- Trial name
- Unity (NCT06684847)
- Testing
- Efgartigimod PH20 SC
- Where
- 303 sites in United States, Argentina and 37 more
- Volunteers
- 631 people
- Sponsor
- argenx
Primary Sjögren's Syndrome
Reliability, Validity of the Turkish Version of the Primary Sjögren Syndrome Quality of Life (PSS-QoL) Questionnaire
The purpose of this study was to investigate adaptation, validity, and reliability of the Turkish version of the Primary Sjögren's Syndrome Quality of Life (PSS-QoL) Questionnaire
- Trial name
- NCT04858464
- Testing
- Survey study
- Where
- Turkey (Türkiye)
- Volunteers
- 75 people
- Sponsor
- Gazi University
Healthy, Sicca Syndrome
A Longitudinal, Observational Biomarker Study in Participants With Primary Sjogren's Syndrome
The main objective of the study is to characterize the gene expression in immune and epithelial cells in salivary gland biopsy samples and blood of pSS (primary Sjögren's syndrome) and non-pSS participants including healthy…
- Conditions
- Healthy, Sicca Syndrome, Sjögren's Syndrome
- Trial name
- NCT02422407
- Testing
- Biopsy
- Where
- 4 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Biogen
Primary Sjögren's Syndrome (pSS)
Exploratory Study on the Efficacy and Safety of Low-Dose Blinatumomab in the Treatment of Moderate to Severe Primary Sjögren's Syndrome
The goal of this clinical trial is to learn if blinatumomab works to treat moderate-to-severe primary Sjögren's Syndrome. It will also learn about the safety of low-dose blinatumomab.
- Trial name
- NCT07852234
- Testing
- Blinatumomab, background treatment
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Beijing Tongren Hospital
Xerostomia, Sjogren's Syndrome
Topical Management of Xerostomia With Dry Mouth Products
Objectives: To assess the effects of topical dry mouth products (toothpaste and mouthwash) containing olive oil, parsley oil, provitamin B5, allantoin, betaine and xylitol in Primary Sjögren's syndrome patients with xerostomia.
- Trial name
- NCT03611283
- Testing
- Mouthwash treatment, Toothpaste treatment
- Volunteers
- 28 people
- Sponsor
- Rosa María López-Pintor Muñoz
Systemic Lupus Erythematosus, Rheumatoid Arthritis (RA)
A Phase 1 Study of QLS2416 Injection in Participants With Autoimmune Diseases
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and efficacy of QLS2416 injection in participants with autoimmune diseases (AID).
- Conditions
- Systemic Lupus Erythematosus, Rheumatoid Arthritis (RA), Primary Sjögren's Syndrome (pSS), Systemic Sclerosis (SSc)
- Trial name
- NCT07906145
- Testing
- QLS2416 Injection
- Volunteers
- 76 people
- Sponsor
- Shanghai Qilu Pharmaceutical Research and Development Center LTD
Primary Sjögren's Syndrome
Autoreactive Anti-Ro/SSA IgE To Determine Primary SjögRen's Syndrome's Disease Activity
Primary Sjögren's syndrome (pSS) can affect various organs, sometimes leads to life-threatening conditions and is always responsible for a decreased quality of life.
- Trial name
- I GET DRY (NCT03003572)
- Testing
- Blood samples
- Where
- 8 sites in France
- Volunteers
- 185 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Sjögren's Syndrome
Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome
The primary objective of this study is to evaluate the efficacy of treatment with either lulizumab or BMS-986142 versus placebo in subjects with moderate to severe primary Sjögren's syndrome as measured by the change from…
- Trial name
- NCT02843659
- Testing
- BMS-931699, BMS-986142
- Where
- 34 sites in United States, Australia and 9 more
- Volunteers
- 45 people
- Sponsor
- Bristol-Myers Squibb
Primary Sjögren's Syndrome
A Study of the Safety and Effectiveness of Efgartigimod in Patients With Primary Sjögren's Syndrome (pSS)
The purpose of this study is to assess the efficacy and safety of human FcRn blocking therapy with efgartigimod compared to placebo, in participants with pSS.
- Trial name
- rho (NCT05817669)
- Testing
- Efgartigimod
- Where
- 17 sites in Belgium, Hungary and 2 more
- Volunteers
- 34 people
- Sponsor
- argenx
Primary Sjögren's Syndrome
UCB Proof of Concept Study in Patients With Primary Sjögren's Syndrome
This is a Phase 2, multicenter, double-blind, placebo-controlled, 12-week proof-of-concept study to assess the efficacy, safety, and tolerability of UCB5857 in subjects with primary Sjögren's Syndrome (pSS).
- Trial name
- NCT02610543
- Testing
- UCB5857
- Where
- 14 sites in France, Italy and 3 more
- Volunteers
- 27 people
- Sponsor
- UCB Celltech
Primary Sjogren's Syndrome, Secondary Sjogren's Syndrome
Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II Study
The primary purpose of this pilot study is to evaluate the efficacy and safety of Abatacept in subjects with Sjogren's Syndrome (SS).
- Conditions
- Primary Sjogren's Syndrome, Secondary Sjogren's Syndrome, Inflammatory Arthritis, Rheumatoid Arthritis
- Trial name
- NCT02027298
- Testing
- Abatacept
- Where
- United States
- Sponsor
- The Cleveland Clinic
Primary Sjögren's Syndrome (pSS)
Efficacy of Tocilizumab in Primary Sjögren's Syndrome.
Primary Sjögren's syndrome (pSS) is a systemic autoimmune disease characterized by lymphocytic infiltration leading to destruction of acinar and ductal cells and loss of glandular parenchyma.
- Trial name
- ETAP (NCT01782235)
- Testing
- Tocilizumab
- Where
- France
- Volunteers
- 110 people
- Sponsor
- University Hospital, Strasbourg, France
Healthy Participants, Primary Sjögren's Syndrome
BMS-986325 in Healthy Participants and Participants With Primary Sjögren's Syndrome
The purpose of this study is to evaluate the safety, tolerability, drug levels, and drug effects of BMS-986325 in healthy participants and participants with primary Sjögren's syndrome.
- Trial name
- NCT04684654
- Testing
- BMS-986325
- Where
- 2 sites in United States, Germany
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Primary Sjögren Syndrome, Lymphoma, Non-Hodgkin
Biomarkers in Primary Sjögren's Syndrome
The clinical spectrum of primary Sjogren Syndrome (pSS)ranges from sicca syndrome to systemic involvement (extraglandular manifestations), including a large number of manifestations that may be the form of presentation or appear…
- Trial name
- pSS (NCT03765593)
- Testing
- Biopsy Salivary Gland
- Volunteers
- 100 people
- Sponsor
- National Council of Scientific and Technical Research, Argentina
Sjögren's Syndrome, Xerostomia
Dexamethasone Irrigation of the Parotid Glands in Primary Sjögren's Syndrome Subjects
Background: Sjögren's syndrome is an autoimmune disease (where the immune system attacks normal body tissues) that affects the salivary glands.
- Trial name
- NCT01316770
- Testing
- Dexamethasone Parotid Irrigation
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
Sjögren´s Syndrome
Primary Sjögren's Syndrome: Impact of Quantitative Anti-Ro52 Antibody Analysis on Patient Prognosis and Stratification (Ro-SjS)
This study aims to evaluate the prognostic value of quantitative anti-Ro52 antibody levels in patients with primary Sjögren's Syndrome.
- Trial name
- Ro-SjS (NCT07414667)
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Central Hospital, Nancy, France
Sjögren's Syndrome
Efficacy and Safety of Belimumab in Subjects With Primary Sjögren's Syndrome
Sjögren's syndrome (SS) is a systemic autoimmune disease characterized by an increase in BAFF (BLyS) levels and a resulting B cell hyperactivity.
- Trial name
- BELISS (NCT01160666)
- Testing
- Belimumab
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Sjögren's Syndrome
Efficacy and Safety of Belimumab in Primary Sjögren's Syndrome
Background and rationale Sjögren's syndrome (SS) is a systemic autoimmune disease characterized by chronic inflammation of salivary and lachrymal glands, frequently accompanied by systemic symptoms.
- Trial name
- NCT01008982
- Testing
- LimphoStat-B
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- University of Udine
Primary Sjögren Syndrome, PET
Exploring the Novel Value of PSMA PET in Sjögren's Syndrome: Integrated Analysis With Established FAPI PET Imaging
Primary Sjögren's syndrome (pSS) is a chronic autoimmune exocrinopathy characterized by lymphocytic infiltration, progressive destruction of salivary gland acini, and varying degrees of functional impairment and fibrosis.
- Trial name
- NCT07324733
- Testing
- ⁶⁸Ga-PSMA PET/CT, ⁶⁸Ga-FAPI PET/CT
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College Hospital